Crititech, Inc.

Mark D Williams

Michael Baltezor

Joseph S Farthing

Matthew McClorey

Jahna Espinosa

Julia K Fischer

Jake Sittenauer

Samuel Campbell

Jacob M Sittenauer

Gary E Clapp

Shelby Clark

Gere Dizerega

Aranza Barreda Abarca

Michael Joseph Bennett

Matthew Mcclorey

Garry E Clapp

Spray applicator stick

The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

Lapatinib particles and uses thereof

Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 mmethods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m/g, methods for making such particles, and methods for-their use as therapeutics.

Glucocorticoid 'nintedanib' particles and their use

Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m/g, methods for their use, and methods for their production are provided.

Niraparib particles and uses thereof

Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m/g, methods for their use, and methods for their production are provided.

Rucaparib particles and uses thereof

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cmand about 0.15 g/cm, and/or a specific surface area (SSA) of at least 18 m/g, 20 m/g, 25 m/g, 30 m/g, 32 m/g, 34 m/g, or 35 m/g. Methods for making and using such compositions are also provided.

Taxane particles and their use

The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Ciprofloxacin polymorph and its use

Methods for making compound particles

Growing community of inventors

Lawrence, KS, United States of America

Mark D Williams